Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
108.12
-8.34 (-7.16%)
At close: Jun 26, 2026, 4:00 PM EDT
107.90
-0.22 (-0.20%)
After-hours: Jun 26, 2026, 7:11 PM EDT
Kymera Therapeutics Employees
Kymera Therapeutics had 238 employees as of December 31, 2025. The number of employees increased by 50 or 26.60% compared to the previous year.
Employees
238
Change (1Y)
50
Growth (1Y)
26.60%
Revenue / Employee
$203,462
Profits / Employee
-$1,245,075
Market Cap
8.89B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Corcept Therapeutics | 730 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Apogee Therapeutics | 261 |
| Nuvalent | 234 |
KYMR News
- 1 day ago - Kymera Therapeutics price target raised to $129 from $106 at Canaccord - TheFly
- 2 days ago - Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment - TipRanks
- 2 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 2 days ago - Kymera Therapeutics rises 18.6% - TheFly
- 3 days ago - Kymera Therapeutics completes enrollment in BROADEN2 trial - TheFly
- 3 days ago - Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 - GlobeNewsWire
- 3 days ago - Kymera Therapeutics appoints Felix Baker as chairman - TheFly
- 3 days ago - Kymera Therapeutics Appoints Felix J. Baker, Ph.D. - GlobeNewsWire